Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
Go back to Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study| (NASDAQ: NTRA) | Delayed: 264.78 +0.56 (0.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.22 | 52 Week High | $13.80 | |||
| Open | $264.22 | 52 Week Low | $6.52 | |||
| Day High | $273.00 | P/E | N/A | |||
| Day Low | $261.59 | EPS | $0.00 | |||
| Volume | 514,229 | |||||
